If we have selected the wrong experience for you, please change it above.
Real-world evidence and Generative AI in the biopharmaceutical industry
2025 benchmark survey
The biopharma industry is experiencing a pivotal shift as Generative AI (GenAI) continues to transform the way real-world evidence (RWE) is designed, generated, and applied. In our latest RWE benchmarking report, survey results reveal widespread recognition of RWE’s value, rising investments in AI, and a need for quantifying the impact. However, while enthusiasm for GenAI is high, talent, trust, and integration remain key challenges for maximizing future value.
Preview our core findings, then download the complete report for further insights and analysis.
RWE is critical to the future of biopharma companies
96% of surveyed biopharma companies consider real-world data and evidence essential to their organizational strategy.
GenAI could be transformative
80% of surveyed executives expect GenAI to significantly impact RWE generation within the next year.
Investments are growing
Nearly all organizations plan to increase RWE investments over the next two to three years, partly to prepare for advanced AI adoption.
Opens in new window
